News
October 25, 2022
Paxlovid stability confirmed
The results of the stability studies initiated by the FFQM on Paxlovid tablets available on the market have now been published in Deutsche Apotheker Zeitung No. 42 of October 20th, 2022, p. 3708-9. The content was determined by high performance liquid chromatography with tandem mass spectrometer detection. The mean content of nirmatrelvir was determined to be 100.3%, i.e. there is no evidence of any relevant degradation of the active substance. The investigations were carried out at the Institute for Biomedical and Pharmaceutical Research, Nuremberg-Heroldsberg.
October 15, 2022
Shelf-life extension Paxlovid® – the rationale alternative to discarding expired batches
Do the Paxlovid® packs already delivered to pharmacies and medical practices need to be discarded timely or by the beginning of 2023 at the latest if the printed shelf-life has been expired? Media reports revealed that the federal government had stockpiled large quantities of the product at the end of 2021 as a precaution in order to avoid a bottleneck in the supply of the patients. However, the prescription rate fell short of expectations in the first nine months, with the result that a number of packs will expire in November 2022 or early 2023.
However, discarding is not inevitable. Rather, a shelf-life extension would be possible in case of proven longer stability in “follow-up” stability tests. Against this background, the Frankfurt Foundation Quality of Medicines initiated investigations into the stability of Paxlovid® tablets collected from the market. The results did not indicate a decrease in the labelled content of active drug ingredient nirmatrelvir or increased levels of degradation products. Therefore, in a published statement, we have suggested extending the expiry date for the packs that have already been delivered, based on the results of follow-up stability investigations conducted by the manufacturer.
June 21, 2022
Prof. Henning Blume was honored with the Presidential Distinction Award 2022 of EUFEPS
Prof. Henning Blume was honored with the Presidential Distinction Award 2022 of EUFEPS
Prof. Henning Blume, chairman of the board of the Frankfurt Foundation Quality of Medicines, was honored with the Presidential Distinction Award 2022 of the European Federation for Pharmaceutical Sciences (EUFEPS). The ceremony was held on the EUFEPS Annual Meeting 2022 which took place in Leiden from 1 – 3 June combined with the Dutch Medicines Days organized by FIGON (Federation for Innovative Drug Research).
The award was given to Henning Blume for outstanding achievement in exceptional leadership, dedication, and support to the European Federation for Pharmaceutical Sciences (https://www.eufeps.org/start.html).
October 1, 2021
Dr. Oliver Scherf-Clavel received the "Quality of Medicines Award"
The „Preis zur Förderung der Arzneimittelqualität“ was awarded for the first time in October. The award winner is junior professor Dr. Oliver Scherf-Clavel.
